Venture Capital & Startup Funding Roundup, August 6, 2026: Bessemer Venture Partners, Gates Frontier, General Atlantic, Google Ventures, Gradient Ventures, Menlo Ventures, Y Combinator & More

An aggressive wave of funding on August 6–7, 2026 underscored investor appetite for automation, AI infrastructure and select biotech bets. Headline rounds included Hadrian’s $1.37 billion Series D at a roughly $7.9 billion valuation, Moove’s $250 million Series C at a reported $2.1 billion valuation, LifeMine Therapeutics’ $188 million Series E, and Expedition’s $115 million Series B. Other notable raises targeted AI agent orchestration and enterprise productivity tools, signaling a preference for durable, revenue-backed automation plays.

"We will 'own, operate and orchestrate' the self-driving ecosystem," company materials say about Moove's pivot from ride-hailing finance to robotaxi fleet ownership — a strategy that helped secure Mubadala Investment Company as lead investor in the $250 million round.

Hadrian’s $1.37 billion round — led by a consortium including WCM Investment Management, Valor Equity Partners, 137 Ventures and Baillie Gifford, with participation from Andreessen Horowitz, Founders Fund and CapitalG — positions the U.S. defense-tech firm as a major supplier of automated manufacturing for military vehicle parts, submarine components and aviation hardware. The raise, which brought Hadrian’s total funding to approximately $2.0 billion, followed rapid growth tied to government contracts and an expansion into a new Alabama submarine facility valued at $2.4 billion in a public-private deal.

• Hadrian — $1.37B Series D; lead investors: WCM Investment Mgmt, Valor Equity, 137 Ventures, Baillie Gifford; other backers: Andreessen Horowitz, Founders Fund, CapitalG; HQ: England (new HQ) / Michigan, USA.
• Moove — $250M Series C; lead: Mubadala Investment Company; co-leads: Woven Capital, Ion Pacific; additional investors: BlueCrest, Sona Asset Mgmt, Raptor Group; HQ: Dubai, UAE; reported metrics: 42,000 vehicles across 14 countries and $420M ARR.
• LifeMine Therapeutics — $188M Series E; investors: Bezos Expeditions (Milky Way Investments), Gates Frontier, Google Ventures, RA Capital; HQ: Watertown, MA; program: immunosuppressant LIFE‑001.
• Expedition — $115M Series B; investors include Merck VC among others (round detailed in sector roundup).
• AI and software rounds: Sapiom $35M Series A; Naïve $28.5M Series A; Omilia $67M (voice-agent platform); Faye $50M Series C (AI-driven travel insurance).

The pattern across deals emphasizes automation at scale and AI that delivers measurable ROI. Investors are reportedly favoring companies that reduce labor and supply-chain friction (Hadrian), monetize fleet finance and operations as autonomous vehicles scale (Moove), or provide infrastructure for AI agent orchestration (Sapiom, Naïve). Enterprise AI winners like Omilia are expected to show revenue traction — Omilia "touts 10× ARR growth to $60 M" — while insurtech plays such as Faye attracted capital for AI-driven claims processing.

Macro conditions are shaping allocations: stabilized interest rates and a dearth of tech IPOs have pushed late-stage capital back into private markets, creating a "dry powder" dynamic that enables outsized rounds for companies addressing long-term needs in defense, transportation and healthcare. Biotech rounds such as LifeMine’s $188 million raise — backed by Bill Gates’s Gates Frontier and Bezos Expeditions among others — indicate that large funds will still back proven science, particularly where clinical progress and credible backing reduce risk.

Outlook: investors appear willing to deploy large checks but with greater discipline — prioritizing automation that produces measurable cost savings or revenue uplift, and biotech programs with strong data or marquee backers. For founders seeking access to the remaining private-market capital, the near-term signal is clear: demonstrate tangible outcomes, clinical or commercial progress, and credible endorsements to tap institutional dry powder.